Pillar 1 -
No trial - however data will be taken from Pillar 2 and 3 human trials to strengthen value of Pillar 1
Pillar 2 -
George Clinical prices POC trial in Australia to be fully funded.
Dr Messina has already applied for CTA which has been approved by TGA.
Trials to be conducted with combination with cyclophosphamide.
Patient criteria TBA. Market value TBA
Trial recruitment to commence Q2
Pillar 3 -
CCSA feasibility shows EM AML is best cost/risk/reward option for RAC Bisantrene single agent approval (and PRV).
MOH in Israel approved trial to commence in Sheba.
Adult trial to commence in Q2 to develop data prior to Paeds trial in Aust in Q3.
MRD trial to run along side EM AML in consolidation course in Sheba.
Ann: Race Initiates Extramedullary AML Preclinical Study, page-97
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |